Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
64.63
+2.50 (4.02%)
At close: Mar 31, 2026, 4:00 PM EDT
64.30
-0.33 (-0.51%)
After-hours: Mar 31, 2026, 5:57 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 423 employees as of December 31, 2025. The number of employees increased by 73 or 20.86% compared to the previous year.
Employees
423
Change (1Y)
73
Growth (1Y)
20.86%
Revenue / Employee
$3,301,681
Profits / Employee
$749,147
Market Cap
7.66B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 423 | 73 | 20.86% |
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 238 |
| Nuvalent | 228 |
HALO News
- 19 days ago - Halozyme Appoints David Ramsay as Interim Chief Financial Officer - PRNewsWire
- 20 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript - Seeking Alpha
- 21 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 25 days ago - U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma - PRNewsWire
- 4 weeks ago - Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 4 weeks ago - Halozyme to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge - Seeking Alpha
- 6 weeks ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript - Seeking Alpha